The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease
AbstractChronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality following allogeneic stem cell transplantation. Current therapies, including corticosteroids and calcineurin inhibitors, are only effective in roughly 50% of cases; therefore, new treatment strategies are under investigation. What was previously felt to be a T cell disease has more recently been shown to involve activation of both T and B cells, as well as a number of cytokines. With a better understanding of its pathophysiology have come more expansive preclinical and clinical trials, many focused on B cell signaling. This report briefly reviews our current understanding of cGVHD pathophysiology and reviews clinical and preclinical trials with B cell-targeted agents. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Rhoades, R.; Gaballa, S. The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease. Biomedicines 2017, 5, 61.
Rhoades R, Gaballa S. The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease. Biomedicines. 2017; 5(4):61.Chicago/Turabian Style
Rhoades, Ruben; Gaballa, Sameh. 2017. "The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease." Biomedicines 5, no. 4: 61.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.